Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline
This article was originally published in The Pink Sheet Daily
Executive Summary
With the end of its cash runway on the horizon, Finland’s Biotie Therapies has received an equity investment of €10 million from Lundbeck and €20 million from institutional investors, after renegotiating the ex-Europe part of its worldwide nalmefene licensing pact.